Zepbound vs Ozempic: Weight-Loss Approval vs Diabetes Drug
Medically reviewed by Medical Advisory Board Last reviewed 2026-07-20
One is FDA-approved specifically for weight loss; the other is a diabetes drug widely used off-label for the same goal
Zepbound (tirzepatide) is FDA-approved specifically for chronic weight management. Ozempic (semaglutide) is FDA-approved for type 2 diabetes and is commonly prescribed off-label for weight loss, with Wegovy as its on-label weight-loss sibling brand. Trial data shows tirzepatide produces more average weight loss, while semaglutide has the longer track record and stronger cardiovascular-outcomes evidence.
This article is for informational purposes only and is not medical advice. Consult a physician before starting, stopping, or switching any prescription medication.
Zepbound and Ozempic are frequently compared because both are once-weekly injections that produce meaningful weight loss — but only one is approved specifically for that purpose. Zepbound (tirzepatide) is FDA-approved for chronic weight management. Ozempic (semaglutide) is FDA-approved for type 2 diabetes; its on-label weight-loss sibling brand is Wegovy. Ozempic is still commonly prescribed off-label for weight loss, which is why the two get compared directly.
Want expert help with your metabolic health?
We can match you with a metabolic-medicine specialist who understands this area — so you get the right doctor, not just any doctor.
Book An Appointment With A Specialist →For the on-label weight-loss comparison of the same two molecules, see our Wegovy vs Zepbound guide. For the diabetes-label comparison, see Ozempic vs Mounjaro.
Zepbound vs Ozempic at a Glance
Both reduce appetite and slow gastric emptying, but through different receptor mechanisms and under different approvals. The table below compares them as they stand in 2026.| Factor | Zepbound (tirzepatide) | Ozempic (semaglutide) |
|---|---|---|
| Drug class | Dual GIP/GLP-1 receptor agonist | GLP-1 receptor agonist |
| FDA approval | Chronic weight management | Type 2 diabetes (weight loss is off-label; see Wegovy) |
| Dosing | 2.5-15 mg weekly injection | 0.25-2 mg weekly injection |
| Average weight loss (trials) | ~20.9% body weight at 72 weeks (SURMOUNT-1) | ~12-15% body weight, off-label diabetes-trial data (SUSTAIN series) |
| CV outcomes data | Emerging (SURPASS-CVOT pending full publication) | Strong (SUSTAIN-6, SELECT trial) |
| Insurance framing | Billed under the weight-loss indication directly | Billed under diabetes coding; off-label weight-loss use complicates coverage |
| Cost (without coverage) | ~$1,000-$1,100/month | ~$900-$1,000/month |
Why the Approval Difference Matters
Zepbound's dedicated weight-management approval gives prescribers and insurers a clear on-label pathway, with prior-authorization criteria built specifically around obesity treatment. Ozempic's diabetes-only approval means a prescription written purely for weight loss is off-label — legal and common, but many insurers require a diabetes diagnosis to cover it, which can leave weight-loss-only patients paying out of pocket.
If weight loss is the sole goal and insurance coverage matters, Wegovy (semaglutide's on-label weight-loss brand) is usually the more insurance-friendly way to access the same molecule as Ozempic. See our Ozempic vs Wegovy comparison for how the two differ despite sharing an active ingredient.
Which Produces More Weight Loss?
Trial evidence favors tirzepatide. The SURMOUNT-1 trial recorded average weight loss of about 20.9% of body weight at 72 weeks on the highest tirzepatide dose. Semaglutide's comparable weight-loss data comes from the STEP trials (Wegovy branding) at roughly 14.9%, since Ozempic itself is dosed and studied primarily for glucose control rather than maximal weight loss. A 2024 real-world study (JAMA) comparing tirzepatide and semaglutide directly found significantly greater weight loss with tirzepatide at one year.
Tirzepatide's dual GIP/GLP-1 mechanism appears to explain the gap — GIP receptor activation seems to amplify GLP-1's appetite-suppressing effect. See our GLP-1 peptides guide for how the mechanisms compare across the whole drug class.
Cardiovascular Evidence and Long-Term Safety
Semaglutide currently has the stronger cardiovascular outcomes evidence. The SELECT trial specifically demonstrated a reduction in major adverse cardiovascular events in people with established heart disease and overweight or obesity, and semaglutide has been on the market since 2017, giving it a longer real-world safety record than tirzepatide. Tirzepatide's cardiovascular outcomes data is still emerging, with the SURPASS-CVOT trial results pending full publication as of 2026.
Both drugs share the same core gastrointestinal side effects — nausea, vomiting, diarrhea, and constipation, most prominent during dose escalation — and both carry an FDA black-box warning about thyroid C-cell tumors based on rodent data.
The Verdict: Which Should You Choose?
The right choice usually depends on your priority and insurance situation, not pure preference:
- Maximizing average weight loss: Zepbound (tirzepatide) has the stronger trial numbers.
- Established cardiovascular disease, or you want the drug with the longest track record: Ozempic's semaglutide, backed by SELECT trial outcomes data.
- Clear on-label weight-loss insurance coverage: Zepbound is already coded for weight management; ask about Wegovy if you specifically want the semaglutide molecule on-label.
- You also have type 2 diabetes: Ozempic directly targets blood sugar under an on-label prescription.
A clinician who knows your full history and insurance situation is the right person to make this call. Take the free assessment to see whether insulin resistance or another metabolic factor should shape your plan before you compare specific drugs with your doctor.
What to Look For in a Body-Composition Scale
A bioimpedance scale trends body fat and muscle rather than just weight — useful when the number stalls but your composition is improving. The absolute body-fat % isn't lab-accurate, so use it for TRENDS at a consistent time of day. Choose one that syncs to an app so you can watch the trend line.
Frequently Asked Questions
Is Zepbound or Ozempic better for weight loss?
Clinical trial data favors tirzepatide (Zepbound's molecule): the SURMOUNT-1 trial showed about 20.9% average body-weight loss at 72 weeks, and a 2024 real-world study found tirzepatide produced significantly more weight loss than semaglutide at one year. Ozempic itself is dosed for diabetes rather than maximal weight loss, so its sibling brand Wegovy is the fairer semaglutide comparison for weight-loss trial data.
Can I take Ozempic instead of Zepbound for weight loss?
Yes, but it would be off-label, since Ozempic is FDA-approved for type 2 diabetes, not weight loss. Many clinicians prescribe it off-label for weight loss, but insurance coverage is often easier for Zepbound (on-label for weight management) or Wegovy (semaglutide's on-label weight-loss brand).
What is the difference between Ozempic and Wegovy if I want weight loss?
They are the same drug, semaglutide, sold under two brand names for two different FDA-approved uses: Ozempic for type 2 diabetes and Wegovy for chronic weight management. If weight loss is your only goal, Wegovy typically has a clearer path to insurance coverage than off-label Ozempic.
Are Zepbound and Ozempic covered by insurance?
Coverage varies significantly by plan. Zepbound is billed directly under its weight-management approval, which some plans cover and others exclude entirely. Ozempic is typically billed under a diabetes diagnosis; using it off-label for weight loss without that diagnosis often means paying out of pocket or seeking Wegovy instead. Always verify your plan's prior-authorization requirements before starting.
Which has better long-term safety data, Zepbound or Ozempic?
Semaglutide (Ozempic/Wegovy) has been on the market since 2017 and has the longer real-world safety record, plus SELECT trial data showing reduced cardiovascular events in people with established heart disease. Tirzepatide (Zepbound/Mounjaro) is newer, with cardiovascular outcomes data still emerging as of 2026.
Topic updates
Get the weekly metabolic health roundup
Insulin resistance, blood sugar, visceral fat, GLP-1 plateaus, metabolic syndrome, and weight-loss physiology.
Check Where You Stand
Take our free health assessment to understand your metabolic, hormonal, and recovery risk factors — and get personalized recommendations.
Take the Free Assessment →Free · Takes 5 minutes · Instant results
Continue Reading
-
What Is Insulin Resistance? Causes, Symptoms & How to Reverse It
What insulin resistance is, how to test for it, and how to reverse it.
-
Hyperinsulinemia
Chronically high insulin: symptoms, causes, how it differs from insulin resistance, and how to reverse it.
-
Metabolic Syndrome — Diagnosis, Risks, and Treatment
The five diagnostic criteria and what they mean for your health.
-
Insulin Resistance Symptoms: 12 Warning Signs
12 clinical warning signs, from acanthosis nigricans to post-meal fatigue.
-
Blood Sugar Crash: Why It Happens and How to Stop It
Reactive hypoglycemia: causes, symptoms, and how to stabilize glucose.
-
Glucose Spikes After Eating: Causes and What to Do
Why blood sugar spikes after eating and what to do about it.
-
Fatigue After Eating: Why Food Makes You Tired
Post-meal fatigue explained — insulin, glucose, and the gut-brain axis.
-
Hypoglycemia Symptoms: Low Blood Sugar Warning Signs
Low blood sugar warning signs and when to seek medical attention.
-
How to Reverse Insulin Resistance Naturally
Evidence-based dietary and lifestyle interventions (3-16 week timeline).
-
Slow Metabolism: Myths, Causes, and What Actually Works
Why metabolism slows, what's myth vs reality, and what the evidence says.
Affiliate disclosure: The Metabolic Journal is reader-supported. Some links above are affiliate or referral links and we may earn a commission at no extra cost to you. As an Amazon Associate we earn from qualifying purchases. Products are chosen on the merits; commissions never influence what we recommend. This is general information, not medical advice — talk to your clinician before acting.